IL-6, which is linked to the ECM, can regulate collagen synthesis by fibroblasts in SSc [34, 35], and EGF was shown to up-regulate TGFRII expression in SSc fibroblasts [36]; thus, EGFR signalling was suggested as a therapeutic target in fibrotic diseases [37]. Here, IL6 is linked to systemic sclerosis.